Acute Effect of Exenatide on Brain Glucose Metabolism
NCT01588418 on ClinicalTrials.gov · last registry update 2017-11-24
A small phase 4 — 15 participants, against a typical 75. The sponsor logged completion for July 2015. Primary outcome, as filed: Effect of Exenatide on Brain (Total Gray Matter) Glucose Metabolism. exenatide is approved in the US, but not for diabetes and prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor type
- Other
- Enrollment
- 15
- Started
- 2010-07
- Primary completion
- 2015-07 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Effect of Exenatide on Brain (Total Gray Matter) Glucose Metabolism
Conditions studied
Impaired Glucose Tolerance (IGT) · Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.